CN112704492A - Method for evaluating levels of several interleukins in serum based on skin autofluorescence - Google Patents
Method for evaluating levels of several interleukins in serum based on skin autofluorescence Download PDFInfo
- Publication number
- CN112704492A CN112704492A CN201911021790.0A CN201911021790A CN112704492A CN 112704492 A CN112704492 A CN 112704492A CN 201911021790 A CN201911021790 A CN 201911021790A CN 112704492 A CN112704492 A CN 112704492A
- Authority
- CN
- China
- Prior art keywords
- interleukin
- skin
- autofluorescence
- intensity
- serum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14546—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring analytes not otherwise provided for, e.g. ions, cytochromes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
- A61B5/0071—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by measuring fluorescence emission
Abstract
The invention discloses a method for evaluating the levels of a plurality of interleukins in serum based on skin autofluorescence; the evaluation method comprises the following steps: (1) detecting the spontaneous fluorescence of the skin tissue at the wavelength of 500-620nm under the excitation of the excitation light of 450-520 nm; (2) detecting the skin autofluorescence intensity; the intensity of this autofluorescence characterizes the levels of interleukin 1 α, interleukin 1 β, interleukin 2, interleukin 5, interleukin 6, and interleukin 10 in the serum. The invention discovers that the skin autofluorescence intensity is in obvious positive correlation with the levels of interleukin 1 alpha, interleukin 1 beta, interleukin 2, interleukin 5, interleukin 6 and interleukin 10 in serum, so that the levels of the interleukins can be estimated noninvasively by detecting the autofluorescence intensity of the skin.
Description
Technical Field
The invention relates to a method for evaluating the levels of interleukin 1 alpha, interleukin 1 beta, interleukin 2, interleukin 5, interleukin 6 and interleukin 10 in serum based on skin autofluorescence.
Background
Interleukin, or interleukin (Interlukin), refers to a lymphokine that interacts with leukocytes or immune cells and is a cytokine of the same genus as blood cell growth factor. The two are mutually coordinated and interacted to jointly complete the functions of hematopoiesis and immunoregulation. Interleukins play an important role in transmitting information, activating and regulating immune cells, mediating the activation, proliferation and differentiation of T and B cells, and in inflammatory responses.
Interleukin 1 β is a pro-inflammatory factor that plays a key role in the immune response of the human body to toxic stimuli both internally and externally to the body. Interleukin 2 plays an important role in T cell proliferation and other key functions. Interleukin 5 stimulates B cells to produce antibodies, which also play an important role in the differentiation and proliferation of eosinophils. Interleukin-6 is a cytokine that plays an important role in the immune response of the human body during the acute phase of the immune response, as well as in the process of hematopoiesis. Interleukin 10 is a cytokine that plays multiple roles in the development of autoimmune diseases and cancer. Interleukin 12(p40) is a cytokine with immune regulation function.
The current main method for detecting the level of the above interleukins in serum is by blood test. This method has the drawback of being invasive and requiring a professional doctor and nurse to perform the operative tests. It is of great value to find a method and technique for non-invasive assessment of these interleukin levels.
Disclosure of Invention
The invention aims to provide a noninvasive method for evaluating the levels of a plurality of interleukins in serum based on skin autofluorescence. The invention discovers that the intensity of the skin green autofluorescence is in a significant positive correlation with the levels of interleukin 1 alpha, interleukin 1 beta, interleukin 2, interleukin 5, interleukin 6 and interleukin 10 in serum, so that the levels of the interleukins in the serum can be non-invasively evaluated by non-invasively evaluating the intensity of the skin green autofluorescence.
The purpose of the invention is realized by the following technical scheme:
in a first aspect, the present invention provides a non-diagnostic therapeutic method for assessing the levels of interleukin 1 α, interleukin 1 β, interleukin 2, interleukin 5, interleukin 6 and interleukin 10 in serum based on skin autofluorescence, the method comprising the steps of:
s1, placing the skin under the excitation light with the wavelength of 450-520nm to excite the autofluorescence of the skin;
s2, detecting an autofluorescence image with the wavelength within the range of 500-620nm emitted by the skin;
s3, analyzing the intensity of the autofluorescence image to obtain the current skin autofluorescence intensity; comparing the current skin autofluorescence intensity with the previous skin autofluorescence intensity to obtain the skin autofluorescence intensity change;
s4, evaluating the levels of interleukin 1 alpha, interleukin 1 beta, interleukin 2, interleukin 5, interleukin 6 and interleukin 10 in the serum according to the obvious positive correlation between the change of the skin autofluorescence intensity and the levels of interleukin 1 alpha, interleukin 1 beta, interleukin 2, interleukin 5, interleukin 6 and interleukin 10 in the serum.
The method is applied to the non-clinical field, can be used for evaluating the levels of interleukin 1 alpha, interleukin 1 beta, interleukin 2, interleukin 5, interleukin 6 and interleukin 10 in the serum of non-disease people, and can also be used for evaluating healthy or sub-healthy people.
Further, in step S1, the excitation light for skin autofluorescence includes at least one of excitation using a normal continuous light output, modulation excitation using electrical modulation, or excitation using pulsed laser light.
Further, in step S1, the wavelength of the excitation light is within the range of 450-500 nm.
Further, in step S2, an autofluorescence image with a wavelength of skin autofluorescence within the range of 500-580nm is detected.
Further, in step S3, the current skin autofluorescence intensity and the past skin autofluorescence intensity are obtained by the same method.
Further, the past skin autofluorescence intensity refers to the skin autofluorescence intensity measured within 2 years before the current test.
Further, in step S3, the current skin green fluorescence intensity is compared with the value of the conventional skin green autofluorescence intensity.
Further, in step S4, the evaluating specifically includes: if the current skin autofluorescence intensity is higher than the previous skin autofluorescence intensity, the higher the level of the existing interleukin 1 alpha, interleukin 1 beta, interleukin 2, interleukin 5, interleukin 6 and interleukin 10 in the serum is, the higher the level of the previous interleukin 1 alpha, interleukin 1 beta, interleukin 2, interleukin 5, interleukin 6 and interleukin 10 is; if the current skin autofluorescence intensity is lower than the previous skin autofluorescence intensity, the lower the levels of interleukin 1 alpha, interleukin 1 beta, interleukin 2, interleukin 5, interleukin 6 and interleukin 10 existing in the serum are.
In a second aspect, the invention relates to a dedicated apparatus for using the aforementioned method. More particularly relates to a special device for evaluating the levels of interleukin 1 alpha, interleukin 1 beta, interleukin 2, interleukin 5, interleukin 6 and interleukin 10 in serum based on skin autofluorescence.
In a third aspect, the invention also relates to a marker for non-invasively assessing the levels of interleukin 1 alpha, interleukin 1 beta, interleukin 2, interleukin 5, interleukin 6 and interleukin 10 in serum, said marker being the intensity of skin autofluorescence.
In a fourth aspect, the present invention relates to an evaluation model for evaluating interleukin in serum based on skin autofluorescence, wherein the levels of interleukin 1 alpha, interleukin 1 beta, interleukin 2, interleukin 5, interleukin 6 and interleukin 10 in the serum of a subject are in a significant positive correlation with the changes in the autofluorescence intensity of the skin of the subject.
Further, the subject's skin autofluorescence intensity change is measured by a method comprising the steps of:
the skin is placed under the excitation light with the wavelength within the range of 450-520nm to excite the autofluorescence of the skin;
detecting an autofluorescence image emitted by the skin with the wavelength within the range of 500-620 nm;
analyzing the intensity of the autofluorescence image to obtain the current skin autofluorescence intensity; and comparing the current skin autofluorescence intensity with the previous skin autofluorescence intensity of the subject to obtain the skin autofluorescence intensity change of the subject.
In a fifth aspect, the invention provides a method for constructing an evaluation model for evaluating interleukin in serum based on skin autofluorescence, which comprises the following steps:
a1, placing the skin of the subject under the excitation light with the wavelength of 450-520nm to excite the autofluorescence of the skin;
a2, detecting the autofluorescence image of the skin with the wavelength in the range of 500-620 nm;
a3, analyzing the intensity of the autofluorescence image to obtain the current skin autofluorescence intensity; comparing the current skin autofluorescence intensity with the past skin autofluorescence intensity of the subject to obtain the skin autofluorescence intensity change of the subject;
a4, the skin autofluorescence intensity characterizing the levels of interleukin 1 alpha, interleukin 1 beta, interleukin 2, interleukin 5, interleukin 6 and interleukin 10 in the serum of the subject.
Compared with the prior art, the invention has the following beneficial effects:
1) the levels of interleukin 1 alpha, interleukin 1 beta, interleukin 2, interleukin 5, interleukin 6 and interleukin 10 in the serum can be non-invasively assessed by non-invasively assessing the intensity of the skin green autofluorescence.
2) The use of skin autofluorescence intensity as a marker for non-invasive assessment of the levels of interleukin 1 alpha, interleukin 1 beta, interleukin 2, interleukin 5, interleukin 6 and interleukin 10 in serum is provided.
Drawings
FIG. 1: the excitation light is 488nm to excite the skin to perform autofluorescence, and the receiving light with the wavelength range of 500-550nm is received; a quantitative graph of correlation between autofluorescence intensity and interleukin 1 alpha;
FIG. 2: the excitation light is 488nm to excite the skin to perform autofluorescence, and the receiving light with the wavelength range of 500-550nm is received; a quantitative graph of correlation between autofluorescence intensity and interleukin 1 beta;
FIG. 3: the excitation light is 488nm to excite the skin to perform autofluorescence, and the receiving light with the wavelength range of 500-550nm is received; a quantitative graph of correlation between autofluorescence intensity and interleukin 2;
FIG. 4: the excitation light is 488nm to excite the skin to perform autofluorescence, and the receiving light with the wavelength range of 500-550nm is received; a quantitative graph of correlation between autofluorescence intensity and interleukin 5;
FIG. 5: the excitation light is 488nm to excite the skin to perform autofluorescence, and the receiving light with the wavelength range of 500-550nm is received; a quantitative graph of correlation between autofluorescence intensity and interleukin 6;
FIG. 6: the excitation light is 488nm to excite the skin to perform autofluorescence, and the receiving light with the wavelength range of 500-550nm is received; quantitative graph of correlation between autofluorescence intensity and interleukin 10.
Detailed Description
The present invention will be described in detail with reference to examples. The following examples will assist those skilled in the art in further understanding the invention, but are not intended to limit the invention in any way. It should be noted that it would be apparent to those skilled in the art that several modifications and improvements can be made without departing from the inventive concept. All falling within the scope of the present invention. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
The term "autofluorescence" as used herein means the phenomenon in which a biomolecule, when irradiated with excitation light of an appropriate wavelength, absorbs the energy of the excitation light into an excited state and then exits the excited state to emit light of a wavelength longer than that of the excitation light.
The term "excitation light" as used in the present invention means light capable of exciting a biomolecule to undergo autofluorescence, and the wavelength should be shorter than the autofluorescence
The term "Interleukin" (or "Interleukin", the english term "Interleukin" is used herein to refer to a lymphokine that interacts with leukocytes or immune cells and is a cytokine belonging to the same genus as blood cell growth factor.
Example 1
Male C57 mice were used and were housed in an animal house at 22-24℃ for 12 hours light/dark cycles and were allowed free access to water. Injecting lipopolysaccharide into the abdominal cavity of the mouse, and performing non-invasive real-time imaging on the skin of the mouse treated by the lipopolysaccharide by using a laser confocal microscope after 1 day and 3 days. The excitation wavelength of the confocal laser scanning microscope can be 450-520nm, and 488nm is selected in this embodiment. The receiving band is 500-620nm, and two receiving bands, 500-550nm and 575-620nm, are selected in this embodiment.
The interleukin was quantitatively detected in the mouse serum 1 day and 3 days later.
The results of correlation between the autofluorescence intensity of the skin of the mouse and the level of interleukin 1 alpha in the serum 3 days after the treatment of the mouse with lipopolysaccharide are shown in FIG. 1, the correlation between the autofluorescence intensity of the skin of the mouse and the level of interleukin 1 beta in the serum 2 is shown in FIG. 2, the correlation between the autofluorescence intensity of the skin of the mouse and the level of interleukin 2 in the serum 3, the correlation between the autofluorescence intensity of the skin of the mouse and the level of interleukin 5 in the serum 4, the correlation between the autofluorescence intensity of the skin of the mouse and the level of interleukin 6 in the serum 5, and the correlation between the autofluorescence intensity of the skin of the mouse and the level of interleukin 10 in the serum 3 days after the treatment of the mouse with lipopolysaccharide are shown in FIG. 6.
As can be seen from FIGS. 1-6, the skin fluorescence intensity allows the detection of interleukin concentration. Meanwhile, the fluorescence intensity of the skin is found to be positively correlated with the levels of interleukin 1 alpha, interleukin 1 beta, interleukin 2, interleukin 5, interleukin 6 and interleukin 10 in the serum. The higher the fluorescence intensity of the skin, the higher the level of these interleukins in the serum. The higher the fluorescence intensity of the skin, the higher the level of these interleukins in the serum.
The above experiments show that the autofluorescence of mice treated with lipopolysaccharide changes, and the change is positively correlated with the level of the above-mentioned interleukins in serum. Therefore, the skin autofluorescence intensity can be used as a marker for non-invasive assessment of the above-mentioned interleukin levels in serum.
Based on the discovery, the invention establishes a method for noninvasive evaluation of serum interleukin concentration based on skin autofluorescence, which comprises the following steps:
1. a method of assessing the levels of interleukin 1 α, interleukin 1 β, interleukin 2, interleukin 5, interleukin 6 and interleukin 10 in serum based on skin autofluorescence comprising:
(1) the skin is placed under excitation light with a wavelength in the range of 450-520nm to excite the autofluorescence of the skin.
(2) Detecting an autofluorescence image emitted by the skin with the wavelength within the range of 500-620 nm;
(3) analyzing the intensity of the autofluorescence image, comparing the intensity of the autofluorescence with the fluorescence intensity of the subject over the test two years;
(4) the serum levels of interleukin 1 α, interleukin 1 β, interleukin 2, interleukin 5, interleukin 6 and interleukin 10 in the test subjects were evaluated according to the following methods: the levels of interleukin 1 alpha, interleukin 1 beta, interleukin 2, interleukin 5, interleukin 6 and interleukin 10 in the blood serum of the tested person are in a significant positive correlation with the change of the autofluorescence intensity of the skin of the tested person. If the existing autofluorescence intensity of the tested person is higher than the former autofluorescence intensity of the tested person, the higher the level of the interleukins existing in the serum of the tested person is. If the existing autofluorescence intensity of the testee is lower than the former autofluorescence intensity of the testee, the lower the existing interleukin level in the serum of the testee is, the lower the former interleukin level of the testee is.
The excitation of skin autofluorescence with excitation light according to the present invention includes at least one of excitation using a normal continuous light output, modulation excitation using electrical modulation, or excitation using pulsed laser.
It will be apparent to those skilled in the art that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention. Therefore, the detailed description and examples of the invention should not be construed as limiting the scope of the invention. The invention is limited only by the appended claims. All documents cited in this application are incorporated herein by reference in their entirety.
Claims (10)
1. A non-diagnostic therapeutic method for assessing the levels of interleukin 1 alpha, interleukin 1 beta, interleukin 2, interleukin 5, interleukin 6 and interleukin 10 in serum based on skin autofluorescence, the method comprising the steps of:
s1, placing the skin under the excitation light with the wavelength of 450-520nm to excite the autofluorescence of the skin;
s2, detecting an autofluorescence image with the wavelength within the range of 500-620nm emitted by the skin;
s3, analyzing the intensity of the autofluorescence image to obtain the current skin autofluorescence intensity; comparing the current skin autofluorescence intensity with the previous skin autofluorescence intensity to obtain the skin autofluorescence intensity change;
s4, evaluating the levels of interleukin 1 alpha, interleukin 1 beta, interleukin 2, interleukin 5, interleukin 6 and interleukin 10 in the serum according to the obvious positive correlation between the change of the skin autofluorescence intensity and the levels of interleukin 1 alpha, interleukin 1 beta, interleukin 2, interleukin 5, interleukin 6 and interleukin 10 in the serum.
2. The method according to claim 1, wherein the excitation of the skin autofluorescence with the excitation light in step S1 comprises at least one of excitation with a common continuous light output, modulated excitation with electrical modulation, or excitation with pulsed laser light.
3. The method as claimed in claim 1, wherein in step S1, the wavelength of the excitation light is in the range of 450 nm and 500 nm.
4. The method as claimed in claim 1, wherein in step S2, an autofluorescence image of skin autofluorescence is detected at a wavelength in the range of 500-580 nm.
5. The method according to claim 1, wherein in step S3, the current skin autofluorescence intensity and the past skin autofluorescence intensity are obtained based on the same method; the past skin autofluorescence intensity refers to the skin autofluorescence intensity measured within 2 years before the current test.
6. The method according to claim 1, wherein in step S3, the current skin green fluorescence intensity is compared with the previous values of skin green autofluorescence intensity.
7. The method according to claim 1, wherein in step S4, the evaluation is in particular: if the current skin autofluorescence intensity is higher than the previous skin autofluorescence intensity, the higher the level of the existing interleukin 1 alpha, interleukin 1 beta, interleukin 2, interleukin 5, interleukin 6 and interleukin 10 in the serum is, the higher the level of the previous interleukin 1 alpha, interleukin 1 beta, interleukin 2, interleukin 5, interleukin 6 and interleukin 10 is; if the current skin autofluorescence intensity is lower than the previous skin autofluorescence intensity, the lower the levels of interleukin 1 alpha, interleukin 1 beta, interleukin 2, interleukin 5, interleukin 6 and interleukin 10 existing in the serum are.
8. A dedicated apparatus for use with the method of any one of claims 1 to 7.
9. A marker for non-invasively assessing the levels of interleukin 1 α, interleukin 1 β, interleukin 2, interleukin 5, interleukin 6 and interleukin 10 in serum, wherein said marker is the intensity of skin autofluorescence.
10. A construction method of an evaluation model for evaluating interleukin in serum based on skin autofluorescence is characterized by comprising the following steps:
a1, placing the skin of the subject under the excitation light with the wavelength of 450-520nm to excite the autofluorescence of the skin;
a2, detecting the autofluorescence image of the skin with the wavelength in the range of 500-620 nm;
a3, analyzing the intensity of the autofluorescence image to obtain the current skin autofluorescence intensity; comparing the current skin autofluorescence intensity with the past skin autofluorescence intensity of the subject to obtain the skin autofluorescence intensity change of the subject;
a4, the skin autofluorescence intensity characterizing the levels of interleukin 1 alpha, interleukin 1 beta, interleukin 2, interleukin 5, interleukin 6 and interleukin 10 in the serum of the subject.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911021790.0A CN112704492A (en) | 2019-10-25 | 2019-10-25 | Method for evaluating levels of several interleukins in serum based on skin autofluorescence |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911021790.0A CN112704492A (en) | 2019-10-25 | 2019-10-25 | Method for evaluating levels of several interleukins in serum based on skin autofluorescence |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112704492A true CN112704492A (en) | 2021-04-27 |
Family
ID=75541454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911021790.0A Pending CN112704492A (en) | 2019-10-25 | 2019-10-25 | Method for evaluating levels of several interleukins in serum based on skin autofluorescence |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112704492A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101469346A (en) * | 2007-12-28 | 2009-07-01 | 上海南方模式生物科技发展有限公司 | Construction of interleukin 1beta specific mouse optical imaging system and use thereof |
| CN102197051A (en) * | 2008-08-28 | 2011-09-21 | 惠氏有限责任公司 | Uses of IL-22, IL-17, and IL-1 family cytokines in autoimmune diseases |
| CN102548466A (en) * | 2009-07-28 | 2012-07-04 | 霍夫曼-拉罗奇有限公司 | Non-invasive in vivo optical imaging method |
| CN105445466A (en) * | 2016-01-19 | 2016-03-30 | 苏州市博纳泰科生物技术有限公司 | Detection method for interleukin 6 and reagent kit of detection method |
-
2019
- 2019-10-25 CN CN201911021790.0A patent/CN112704492A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101469346A (en) * | 2007-12-28 | 2009-07-01 | 上海南方模式生物科技发展有限公司 | Construction of interleukin 1beta specific mouse optical imaging system and use thereof |
| CN102197051A (en) * | 2008-08-28 | 2011-09-21 | 惠氏有限责任公司 | Uses of IL-22, IL-17, and IL-1 family cytokines in autoimmune diseases |
| CN102548466A (en) * | 2009-07-28 | 2012-07-04 | 霍夫曼-拉罗奇有限公司 | Non-invasive in vivo optical imaging method |
| CN105445466A (en) * | 2016-01-19 | 2016-03-30 | 苏州市博纳泰科生物技术有限公司 | Detection method for interleukin 6 and reagent kit of detection method |
Non-Patent Citations (2)
| Title |
|---|
| MINGCHAO ZHANG, ET AL: "Keratin-Based Epidermal Green Autofluorescence is a Common Biomarker of Organ Injury", 《BIORXIV》 * |
| 汪丽蕙，林传骧等主编: "《今日内科 血液疾病•内分泌疾病分册》", 30 November 1991 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Blanchard | Elevated basal levels of cardiovascular responses in Vietnam veterans with PTSD: A health problem in the making? | |
| JP3151669B2 (en) | Apparatus for measuring pH of target, method of using the apparatus and use thereof | |
| TW201737864A (en) | Tissue classification method using time-resolved fluorescence spectroscopy and combination of monopolar and bipolar cortical and subcortical stimulator with time-resolved fluorescence spectroscopy | |
| WO2015051013A9 (en) | A wearable system and method to measure and monitor ultraviolet, visible light, and infrared radiations in order to provide personalized medical recommendations, prevent diseases, and improve disease management | |
| CN106226275A (en) | A kind of based on fingernail autofluorescence as the detection method of biomarker of detection stroke onset and application thereof | |
| Beltran et al. | Gastrointestinal ischemia monitoring through impedance spectroscopy as a tool for the management of the critically ill | |
| Connor et al. | Differences in age-related alterations in muscle contraction properties in rat tongue and hindlimb | |
| Skidmore et al. | The effect of advanced age on the electrode-neuron interface in cochlear implant users | |
| Zong et al. | Motor unit number of the first dorsal interosseous muscle estimated from CMAP scan with different pulse widths and steps | |
| CN112704492A (en) | Method for evaluating levels of several interleukins in serum based on skin autofluorescence | |
| CN112710640A (en) | Method for evaluating interleukin level in serum based on epidermal keratin and fragment content | |
| Ju et al. | Long-term two-photon imaging of spinal cord in freely behaving mice | |
| Kumar et al. | Heart rate variability during examination stress in medical students | |
| CN106264469A (en) | The detection method of the biomarker damaged as predicted detection ultraviolet light based on Epidermal Keratin and associated protein thereof and application thereof | |
| CN112704472A (en) | Method for evaluating chemotactic/growth factor level in serum based on skin autofluorescence | |
| Shi et al. | Preliminary research on monitoring of cerebral ischemia using electrical impedance tomography technique | |
| CN112710639A (en) | Method for evaluating chemotactic/growth factor level in serum based on epidermal keratin | |
| CN110881952A (en) | Method for detecting human body clogging product based on human body skin autofluorescence intensity and spatial distribution and application thereof | |
| CN113261918A (en) | Method for designing instrument for screening and detecting lung infection | |
| CN110623633A (en) | Method for detecting human tissue inflammation based on skin autofluorescence and application thereof | |
| RU2190350C2 (en) | Method for noninvasive express- diagnostics | |
| KR20160017484A (en) | Bio-signal measurement device and method using dichromatic incident light | |
| CN113729634B (en) | Skin photoacoustic image processing method | |
| CN109394171A (en) | Physiological characteristic sensing system | |
| RU88932U1 (en) | DEVICE FOR RECORDING AND CORRECTION OF WAVE PROCESSES OF BIO OBJECTS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210427 |